# AASLD-FDA-NIH-PhRMA- Hepatotoxicity Steering Group Meeting
# Strathmore Music Center, North Bethesda MD
# January 25 – 26, 2006

## *DILI – WHERE DO WE GO FROM HERE?*

### January 25, 2006

| | | |
|---|---|---|
| 8:00 AM | **CHECK-IN and CONTINENTAL BREAKFAST** | |
| 8:30 AM | Welcome | John Senior *(FDA)* |
| 8:35 AM | Introductions; meeting plans | Lana Pauls *(FDA)* |

### Session I: Non-Clinical Prediction
### (Moderator - Patrick Wier)
*Can pre/non-clinical studies really predict that a drug will be hepatotoxic to people?*

| | | |
|---|---|---|
| 8:45 AM | Integrating liver toxicogenomics with clinical pathology and histopathology in preclinical studies – The GSK experience | Patrick Wier *(GSK)* |
| 9:15 AM | Metabonomics in preclinical assessment of hepatic toxicity | Don Robertson *(Pfizer)* |
| 9:45 AM | Biofluid metabolite profiling to assess preclinical hepatotoxicity | Craig Thomas *(Lilly)* |
| 10:05 AM | New developments in preclinical prediction of human hepatotoxicity | Jim Sanders *(J & J)* |
| 10:25 AM | **COFFEE BREAK** | |
| 10:45 AM | Liver toxicity biomarkers study CRADA (with FDA) | Robert McBurney *(BG-Med)* |
| 11:10 AM | Genomics and beyond – Hepatic toxicity biomarkers from prospective safety studies | Yvonne Dragan *(FDA-NCTR)* |
| 11:30 AM | Panel discussion: Predictive value of non-clinical studies | All |
| 12 Noon | **LUNCH** | |

### Session II: Liver Adaptation to Injury
### (Moderator - Paul Watkins)
*How does the liver adapt to xenobiotic injury and become tolerant?*

| | | |
|---|---|---|
| 1:00 PM | Tacrine, isoniazid, and ximelagatran: development of clinical tolerance | John Senior *(FDA)* |
| 1:15 PM | Cytokines and/or other factors protecting the liver from drug-induced injury | Lance Pohl *(NIH)* |
| 1:35 PM | Liver tissue repair, survival factors, and injury adaptation | Hari Mehendale *(U LA)* |
| 1:55 PM | Role of regeneration in hepatoprotection | Rebecca Taub *(Roche)* |
| 2:15 PM | Immune tolerance development | Jack Uetrecht (U Toronto) |

| | | |
|---|---|---|
| 2:35 PM | **BREAK** | |
| 2:50 PM | Panel discussion, questions | All |
| 3:10 PM | The way forward toward improved biomarkers | Paul Watkins *(U NC)* |
| 3:25 PM | Proposal for SNP analysis of DILIN genomic bank | Dan Burns *(GSK)* |
| 3:45 PM | Closing panel discussion and questions | All |
| 4:00 PM | Adjourn | |

**Thursday, January 26**

**Session III: Attribution of Causality**
**(Moderator - Len Seeff)**
*How likely is it that a drug really caused the injury, and if so which drug?*

| | | |
|---|---|---|
| 8:00 AM | **CONTINENTAL BREAKFAST** | |
| 8:30 AM | Problems of establishing causality | Leonard Seeff *(NIH)* |
| 8:45 AM | Use and critique of the "RUCAM" | Jim Freston *(U CT)* |
| 9:05 AM | Method of DILIN in establishing causality | Don Rockey *(U TX)* |
| 9:25 AM | Determining causation of acute liver failure | Will Lee *(UT-SW)* |
| 9:45 AM | Immunological tests for improving causality assessment | Herb Bonkovsky *(U CT)* |
| 10:05 AM | **BREAK** | |
| 10:30 AM | Can we replace opinion consensus with a Bayesian process? | Tim Davern (*UCSF*) |
| 11:00 AM | Characterization of serious DILI from AERS reports | Mark Avigan *(FDA)* |
| 11:20 AM | Update on the DILIN network | Naga Chalasani *(IU)* |
| 11:40 AM | What role does industry want/should play in DILIN? | All |
| 12:15 PM | **ADJOURN** | |

***Thanks to PhRMA, AASLD, and DILIN for their support of this meeting!***